Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.
P/B ratio for Ipca Laboratories Limited (IPCALAB.NS)
P/B ratio as of 2023: 4.97
According to Ipca Laboratories Limited's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 4.97. At the end of 2022 the company had a P/B ratio of 3.52.
P/B ratio history for Ipca Laboratories Limited from 2004 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 4.97 |
| 2022 | 3.52 |
| 2021 | 4.92 |
| 2020 | 5.13 |
| 2019 | 4.85 |
| 2018 | 3.94 |
| 2017 | 3.12 |
| 2016 | 3.21 |
| 2015 | 3.22 |
| 2014 | 3.63 |
| 2013 | 5.44 |
| 2012 | 4.27 |
| 2011 | 3.37 |
| 2010 | 3.58 |
| 2009 | 3.89 |
| 2008 | 1.31 |
| 2007 | 2.62 |
| 2006 | 3.18 |
| 2005 | 2.37 |
| 2004 | 2.30 |